• 19. 10, 15 MDxHealth to Participate in Prospective 4M Clinical Study Evaluating Synergy of MRI and SelectMDx for Prostate Cancer
  • MDxHealth, has entered into an agreement with Radboud University Medical Center in Nijmegen, The Netherlands, for the.... Read more..

  • 13. 10, 15 MDxHealth Launches SelectMDx liquid biopsy in Europe
  • MDxHealth SA (Euronext: MDXH.BR), announced today, the commercia.... Read more..

  • 18. 09, 15 MDxHealth acquires NovioGendix to expand uro-oncology product offering
  • MDxHealth SA (Euronext Brussels: MDXH) (the .... Read more..

  • 28. 05, 15 QUATTRO: A next generation test
  • The serum level of .... Read more..

  • 10. 12, 14 Gisèle Leyten over Quattro Urine test op Radio 1
  • Gisèle Leyten is op Radio 1 geïnterviewd over de nieuwe urinetest die de agressiviteit van prostaatkanker kan aantonen: de Quattro te.... Read more..


    NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic research and service company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnostic assays for the uro-oncological practice.


    NovioGendix Research focuses on biomarker-based diagnostic product development for uro-oncological diseases. In its R&D program the company conducts multiple retrospective and prospective clinical studies in prostate-, bladder- and kidney cancer.


    NovioGendix Servicelab has transferred the Progensa® PCA3 testing services to DDL-NMDL in Rijswijk, the Netherlands.